# HepATocellular Cancer Hcv Therapy Study

> **NCT04546802** · PHASE3 · WITHDRAWN · sponsor: **Bayside Health**

## Conditions studied

- Hepatocellular Carcinoma
- Hepatoma
- Liver Cell Carcinoma
- Hepatitis C

## Interventions

- **DRUG:** Elbasvir / Grazoprevir Oral Tablet

## Key facts

- **NCT ID:** NCT04546802
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09
- **Primary completion:** 2021-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment will be too difficult due to available PBS funded treatment and recent Australian clinical guidelines will conflict with the premise of the study.
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546802, "HepATocellular Cancer Hcv Therapy Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04546802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*